Comparison of outcomes of second-line durvalumab plus tremelimumab versus lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
PLOS One · 2026
DOI: 10.1371/journal.pone.0341395 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift PLOS One, 2026. Verfasst von Chinatsu Nishioka und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, The University of Osaka, Graduate School of Medicine, Suita, Osaka, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Antibodies, Monoclonal, Humanized, Quinolines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Aim The optimal second-line therapy following first-line atezolizumab plus bevacizumab remains unascertained. In this study, we compared second-line durvalumab plus tremelimumab with lenvatinib after first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma (uHCC).
Methods
In this retrospective, open-label, non-randomized comparative study, we analyzed real-world data derived from a prospectively registered observational cohort of patients with uHCC who received durvalumab plus tremelimumab (the Dur/Tre group, n = 14) or lenvatinib (the Len group, n = 67) as second-line therapy after first-line atezolizumab plus bevacizumab. Tumor response was assessed using the RECIST criteria version 1.1. Progression-free survival (PFS), overall survival (OS), adverse events (AEs), and changes in the albumin–bilirubin (ALBI) score were compared between the groups.
Results
The objective response and disease control rates were 7.7% and 15.4% in the Dur/Tre group and 23.3% and 76.7% in the Len group, respectively. The median PFS was 1.7 vs. 4.2 months (p < 0.001) and median OS was 5.3 vs. 14.0 months (p = 0.047) in the Dur/Tre and Len groups, both significantly favoring lenvatinib. Multivariable analysis showed that lenvatinib treatment was an independent predictor of longer PFS, and a neutrophil-to-lymphocyte ratio ≥ 3 was an independent predictor of worse OS. Grade ≥ 3 AEs were more frequent with lenvatinib than with durvalumab plus tremelimumab (70.1% vs. 21.4%; p = 0.002). At week 4, the ALBI score was maintained with durvalumab plus tremelimumab (−2.30 to −2.21; p = 0.318) but worsened with lenvatinib (−2.36 to −1.97; p < 0.001).
Conclusions
After first-line atezolizumab plus bevacizumab, second-line lenvatinib achieved superior disease control and longer survival than durvalumab plus tremelimumab. However, grade ≥ 3 AEs were more frequent with lenvatinib than with durvalumab plus tremelimumab. Careful AE management is therefore important when selecting therapy for individual patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, The University of Osaka, Graduate School of Medicine, Suita, Osaka, Japan.
- Department of Gastroenterology and Hepatology, Kansai Rosai Hospital, Amagasaki, Hyogo, Japan.
- Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Osaka, Japan.
- Department of Gastroenterology and Hepatology, Ikeda Municipal Hospital, Ikeda, Osaka, Japan.
- Department of Gastroenterology and Hepatology, Osaka General Medical Center, Osaka, Osaka, Japan.
- Department of Gastroenterology and Hepatology, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Hyogo, Japan.
ORCID-Profile: Yuki Tahata, Kazuhiro Murai, Ryotaro Sakamori, Atsushi Hosui, Hayato Hikita
Zitieren
APA
Nishioka, C., Tahata, Y., Maesaka, K., Kai, M., Shirai, K., Murai, K., Makino, Y., Saito, Y., Nozaki, Y., Nakabori, T., Ishida, H., Yakushijin, T., Iio, S., Tatsumi, N., Imanaka, K., Kakita, N., Sakamori, R., Hosui, A., Miyazaki, M., …, & Takehara, T. (2026). Comparison of outcomes of second-line durvalumab plus tremelimumab versus lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. PLOS One. https://doi.org/10.1371/journal.pone.0341395
Vancouver
Nishioka C, Tahata Y, Maesaka K, Kai M, Shirai K, Murai K, et al. Comparison of outcomes of second-line durvalumab plus tremelimumab versus lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. PLOS One. 2026. doi:10.1371/journal.pone.0341395
BibTeX
@article{Nishioka2026,
author = {Nishioka, Chinatsu and Tahata, Yuki and Maesaka, Kazuki and Kai, Machiko and Shirai, Kumiko and Murai, Kazuhiro and Makino, Yuki and Saito, Yoshinobu and Nozaki, Yasutoshi and Nakabori, Tasuku and Ishida, Hisashi and Yakushijin, Takayuki and Iio, Sadaharu and Tatsumi, Nobuyuki and Imanaka, Kazuho and Kakita, Naruyasu and Sakamori, Ryotaro and Hosui, Atsushi and Miyazaki, Masanori and Matsumoto, Kengo and Nakahara, Masanori and Doi, Yoshinori and Sakakibara, Mitsuru and Hikita, Hayato and Kodama, Takahiro and Takehara, Tetsuo},
title = {Comparison of outcomes of second-line durvalumab plus tremelimumab versus lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0341395}
}
EUVIMED